Evogene Reports Third Quarter 2024 Financial Results
Evogene Ltd. - Ordinary Shares (EVGN)
Last evogene ltd. - ordinary shares earnings: 2/28 07:00 am
Check Earnings Report
US:NYSE Investor Relations:
evogene.com/investor-relations
Company Research
Source: PR Newswire
Conference call and webcast: today, November 21, 2024, 9:00 am ETFinancial Highlights:In the first nine months of 2024, total revenues reached approximately $6.9 million, compared to approximately $5.1 million in the first nine months of 2023.In Q3 2024, total revenues reached approximately $1.8 million, compared to approximately $3.8 million in Q3 2023. The revenues in Q3 2024 are mainly based on Casterra's seed sales. The revenues in Q3 2023 included a license fee payment of $2.5 million received by Lavie Bio.For the full year 2024, Evogene anticipates continued revenue growth, compared to the previous year, mainly due to Casterra's supply of existing seed orders.G&A expenses in Q3 2024 included expenses of approximately $1.4 million resulting from Evogene's fundraising and an allowance for doubtful debt from one of Casterra's seed suppliers. The remaining G&A expenses in Q3 2024 amounted to approximately $1.5 million, unchanged compared to Q3 2023.In the first nine months of 2024,
Show less
Read more
Impact Snapshot
Event Time:
EVGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EVGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EVGN alerts
High impacting Evogene Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
EVGN
News
- Lavie Bio Advances its Bio-Fungicide LAV321, Targeting Downy Mildew, to Pre-Commercial Stage Following Successful 2024 Field Trial Results [Yahoo! Finance]Yahoo! Finance
- Lavie Bio Advances its Bio-Fungicide LAV321, Targeting Downy Mildew, to Pre-Commercial Stage Following Successful 2024 Field Trial ResultsPR Newswire
- Evogene Ltd. (NASDAQ: EVGN) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Lavie Bio Announces Commercial Expansion of Yalos® as Seed-Treatment for Soybean, Following Successful Field TrialsPR Newswire
- Evogene Ltd. (NASDAQ: EVGN) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
EVGN
Earnings
- 3/7/24 - Beat
EVGN
Sec Filings
- 11/21/24 - Form 424B3
- 11/21/24 - Form 6-K
- 10/15/24 - Form SC
- EVGN's page on the SEC website